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1. Introduction {#ags312002-sec-0005}
===============

Albeit recent advancements in surgical techniques and perioperative care, the postoperative morbidity rate is as high as approximately 40% after esophageal cancer surgery,[1](#ags312002-bib-0001){ref-type="ref"}, [2](#ags312002-bib-0002){ref-type="ref"} and 20--30% after both gastric cancer surgery[3](#ags312002-bib-0003){ref-type="ref"}, [4](#ags312002-bib-0004){ref-type="ref"}, [5](#ags312002-bib-0005){ref-type="ref"} and colorectal surgery.[6](#ags312002-bib-0006){ref-type="ref"}, [7](#ags312002-bib-0007){ref-type="ref"}, [8](#ags312002-bib-0008){ref-type="ref"} Various reports have shown that such postoperative complications frequently reduce the overall survival (OS) as well as cancer‐specific survival after major surgery for cancer.[9](#ags312002-bib-0009){ref-type="ref"} In particular, severe postoperative complications are associated with impaired long‐term survival after gastroesophageal and pancreatic cancer surgery.[10](#ags312002-bib-0010){ref-type="ref"} One possible explanation for this phenomenon is that the changes in patient immunological responses trigger the progression of residual disease into a clinically manifest recurrence.[11](#ags312002-bib-0011){ref-type="ref"} Some research has shown a negative impact of postoperative complications on survival outcomes. However, several other studies have concluded that surgical complications have no negative effect on survival rates and that these rates depend exclusively on the pathological stage of the tumor.[12](#ags312002-bib-0012){ref-type="ref"} Lerut *et al*.[13](#ags312002-bib-0013){ref-type="ref"} have reported that the modified Clavien classification, in addition to the microscopic residual tumor and extracapsular lymph node involvement, is a useful prognostic indicator of early recurrence and its timing. They have noted that achieving esophagectomy without postoperative complications is of utmost importance because of their potential negative effect on early oncological outcomes.[13](#ags312002-bib-0013){ref-type="ref"} Recent advances in endoscopic diagnosis and clinical radiology in Japan allow early detection of gastric cancer, and therapeutic strategies have been established in some clinical trials. D2 lymph node dissection is safely carried out with low mortality and morbidity and provides favorable oncological outcomes.[12](#ags312002-bib-0012){ref-type="ref"}, [13](#ags312002-bib-0013){ref-type="ref"} However, in clinical practice, postoperative complications do occur, causing some practical problems including longer hospital stay, excessive weight loss with sarcopenia, psychological damage, and delay of adjuvant chemotherapy in advanced cases. The incidence of postoperative complications as a detrimental prognostic factor has recently attracted considerable attention. The impact of postoperative complications on oncological outcomes has also been investigated in patients undergoing colorectal cancer resection. However, the results have been inconsistent. In 2011, Mirnezami *et al*.[14](#ags312002-bib-0014){ref-type="ref"} published a meta‐analysis of the effects of anastomotic leakage on oncological outcomes. They concluded that anastomotic leakage has a negative prognostic impact on local recurrence and cancer‐specific survival.

Acute lung injury induced by the overproduction of inflammatory cytokines can lead to pneumonia after esophageal surgery.[15](#ags312002-bib-0015){ref-type="ref"}, [16](#ags312002-bib-0016){ref-type="ref"} For the improvement of long‐term survival, it is essential to minimize mortality by optimizing surgical techniques and perioperative care.[17](#ags312002-bib-0017){ref-type="ref"}, [18](#ags312002-bib-0018){ref-type="ref"}, [19](#ags312002-bib-0019){ref-type="ref"} In addition, severe infections, pulmonary complications, and liver dysfunction require extended intensive care and long hospital stays for some patients.[9](#ags312002-bib-0009){ref-type="ref"}, [20](#ags312002-bib-0020){ref-type="ref"} A history of such postoperative complications increases the likelihood of poor survival. The effect of body mass index (BMI) on oncological outcomes after major resection for cancer has also been investigated.[20](#ags312002-bib-0020){ref-type="ref"}, [21](#ags312002-bib-0021){ref-type="ref"}, [22](#ags312002-bib-0022){ref-type="ref"}, [23](#ags312002-bib-0023){ref-type="ref"} Although the majority of the studies show a significant association between high BMI and postoperative morbidity, the association of BMI with long‐term oncological outcomes is still controversial. The effects of BMI and postoperative complications might differ depending on the type of operation and/or the type of cancer. Esophageal cancer surgery is probably one of the most stressful types of surgery. Moreover, postoperative complications after esophagectomy can sometimes be fatal.

In the present study, we re‐evaluated the clinical impact of postoperative morbidity on oncological outcome by systematically reviewing recent publications (from 2011 onward), mainly focusing on long‐term patient survival. In addition, we discuss possible mechanisms of this phenomenon. With the present review, we hope to develop a foundation for future guidelines of Japanese Association of Gastroenterological Surgery for perioperative care and postoperative complication management.

2. Methods {#ags312002-sec-0006}
==========

2.1. Research themes and study selection criteria {#ags312002-sec-0007}
-------------------------------------------------

The present review was based on three types of surgery: (i) esophageal cancer surgery; (ii) gastric cancer surgery; and (iii) colorectal cancer surgery. Articles including information related to these research themes were searched by H.S., Y.H., T.F., and K.O. independently using PubMed and MEDLINE in December 2015. In PubMed, 'esophageal cancer', 'gastric cancer', 'colorectal cancer', and 'postoperative complication' were used as search terms. In MEDLINE, the following search terms were used (advanced search system): 1. incidence.sh.; 2. Mortality.sh.; 3. Follow‐Up Studies.sh.; 4. "prognos\*."tw.; 5. "predict\*."tw.; 6. 2 or 3 or 4 or 5; 7. "esophag\*."ab. (or "gastric."ab. or "colorectal."ab.); 8. "postoperative complication\*."ab.; 9. "postoperative morbid\*."ab.; 10. 8 or 9; 11. "esophag\*."ti. (or "gastric."ab. or "colorectal."ab.); 12. 10 and 11; 13. 6 and 12. Authors (H.S., Y.H., and T.F.) evaluated the relevance of each article and categorized it as relevant or irrelevant. Irrelevant articles were excluded from the review.

2.2. Data extraction {#ags312002-sec-0008}
--------------------

Key messages and information were extracted from each article and organized by the authors. In order to evaluate the impact of postoperative complications on long‐term survival, we conducted a publication‐based meta‐analysis. The following information from the eligible articles was used: authors, title, countries of origin, publication year, total sample size, study design, study period, variables used for the statistical adjustment, definition of complication, conclusion, and the summary statistics (hazard ratios and their 95% confidence intervals \[CI\]) for outcomes. Primary outcome measure of the meta‐analysis was OS. Postoperative complications were evaluated using the Clavien‐Dindo classification.[24](#ags312002-bib-0024){ref-type="ref"} Complications with Clavien‐Dindo grade II or higher were defined as severe complications.

2.3. Statistical analysis {#ags312002-sec-0009}
-------------------------

For the meta‐analysis, quantitative data were pooled using the random effects inverse variance weighted meta‐analysis in STATA 13 (StataCorp, College Station, TX, USA). If the adjusted hazard ratio was not reported or it was missing, we treated it as missing and did not include it in the summary statistics calculations. The hazard ratio and the corresponding 95% CI for OS were calculated for each study to compare patients with and without postoperative complications. Heterogeneity between the trials and groups of studies was measured using the *I* ^2^ statistics, which indicate the percentage of variance in a meta‐analysis that is attributable to the study heterogeneity.[25](#ags312002-bib-0025){ref-type="ref"} All reported *P*‐values are two‐tailed and *P*‐values \<0.05 were considered statistically significant.

3. Results {#ags312002-sec-0010}
==========

3.1. Studies included in the present review {#ags312002-sec-0011}
-------------------------------------------

Our systematic search identified 372 articles using PubMed and 871 articles using MEDLINE. We manually found one additional eligible paper and included it in our analysis. We considered 80 studies (41 studies of esophageal cancer, 21 studies of gastric cancer, and 18 studies of colorectal cancer) that were eligible based on title and abstract. After a full‐text search, a final set of 23 studies (six studies of esophageal cancer, six studies of gastric cancer, and 11 studies of colorectal cancer) was used for the meta‐analysis of the impact of postoperative complications on long‐term patient survival. The PRISMA flow diagram[26](#ags312002-bib-0026){ref-type="ref"} for the present study is shown in Figure S1.

3.2. Prognostic impact of postoperative complications after esophageal cancer surgery {#ags312002-sec-0012}
-------------------------------------------------------------------------------------

Ten studies evaluated the prognostic impact of postoperative complications on long‐term survival. Four out of the 10 eligible studies did not report the hazard ratios of postoperative complications because it was not a statistically significant factor (based on univariate analysis using a variable selection process).[27](#ags312002-bib-0027){ref-type="ref"}, [28](#ags312002-bib-0028){ref-type="ref"}, [29](#ags312002-bib-0029){ref-type="ref"}, [30](#ags312002-bib-0030){ref-type="ref"} Thus, we combined the hazard ratios of six remaining studies which adjusted for several confounders in the multivariate model. The overall hazard ratio for postoperative OS was 1.67 (95% CI = 1.31--2.12), as illustrated in Figure [1](#ags312002-fig-0001){ref-type="fig"} (statistically significant heterogeneity among the studies is shown \[*P *= 0.001\]). The information found in each study is listed in Table [1](#ags312002-tbl-0001){ref-type="table-wrap"}.

![Postoperative morbidity and long‐term survival after radical surgery for esophageal cancer. BMI, body mass index.](AGS3-1-11-g001){#ags312002-fig-0001}

###### 

Multivariate analyses of prognostic factors for patients after esophageal cancer surgery

  Author                                                             Year   No. patients   Definition of complication                                                              Conclusion
  ------------------------------------------------------------------ ------ -------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Yamashita *et al*.[1](#ags312002-bib-0001){ref-type="ref"}         2016   255            Infectious complication                                                                 Pulmonary infection is associated with unfavorable prognosis.
  Aahlin *et al*.[10](#ags312002-bib-0010){ref-type="ref"}           2016   1965           Deep infection, deep hemorrhage, anastomotic dehiscence, reoperation for other causes   Major postoperative complications are associated with impaired long‐term survival.
  Booka *et al*.[33](#ags312002-bib-0033){ref-type="ref"}            2015   402            Increased Clavien‐Dindo classification 2, pneumonia                                     Pneumonia has a negative impact on overall survival after esophagectomy.
  Baba *et al*.[2](#ags312002-bib-0002){ref-type="ref"}              2015   502            Increased Clavien‐Dindo classification 2, pneumonia                                     Postoperative pulmonary complications might be an independent predictor of poor long‐term survival in patients undergoing resection of esophageal squamous cell carcinoma.
  van der Schaaf *et al*.[32](#ags312002-bib-0032){ref-type="ref"}   2014   1822           Re‐operation within 30 days                                                             Re‐operation within 30 days of primary esophageal resection is associated with increased mortality.
  Rutegård *et al*.[31](#ags312002-bib-0031){ref-type="ref"}         2012   567            Respiratory complication                                                                Occurrence of surgical complications might be an independent predictor of poor long‐term survival.
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D\'Annoville *et al*.[30](#ags312002-bib-0030){ref-type="ref"} reported that when postoperative mortality is excluded, postoperative complications did not affect disease‐free survival in patients with complete resection. This deserves substantial information regarding the prognosis of a subgroup of patients in critical situations where incrementing intensive care is debated. In addition, Xia *et al*.[29](#ags312002-bib-0029){ref-type="ref"} have reported that major perioperative morbidity does not have a negative impact on long‐term survival and that tumor characteristics at the time of resection are the most important determinants of long‐term survival. Based on the patient population at a center with a long experience of esophageal cancer surgery, Lindner *et al*. examined the occurrence of general and esophageal cancer surgery‐specific perioperative complications.[28](#ags312002-bib-0028){ref-type="ref"} Their results have demonstrated that these complications did not affect the long‐term survival of esophageal cancer patients.

On the basis of the data from a Swedish national database cohort study, Rutegård *et al*. have concluded that surgical complications might be independent predictors of poor long‐term survival in patients undergoing esophageal cancer resection, including patients who survived the postoperative period.[31](#ags312002-bib-0031){ref-type="ref"}, [32](#ags312002-bib-0032){ref-type="ref"} This large, population‐based, nationwide cohort study has shown that re‐operation within 30 days of primary esophageal resection is associated with increased mortality, even when the initial 3 months after surgery is excluded. Similarly, three independent single institutes in high‐volume centers of Japan have shown that pneumonia has a negative impact on OS after esophagectomy. The incidence of postoperative infectious complications and, in particular, pulmonary infections, is associated with unfavorable prognosis in patients with esophageal cancer undergoing preoperative chemotherapy.[1](#ags312002-bib-0001){ref-type="ref"}, [2](#ags312002-bib-0002){ref-type="ref"}, [33](#ags312002-bib-0033){ref-type="ref"}

Intense postoperative inflammatory response frequently observed in patients with severe postoperative pneumonia is significantly correlated with poor postoperative survival. Therefore, the oncological benefit of reducing postoperative inflammation in esophageal cancer should be investigated.[27](#ags312002-bib-0027){ref-type="ref"} Based on risk stratification for esophagectomy using a Japanese nationwide database, Takeuchi *et al*.[34](#ags312002-bib-0034){ref-type="ref"} observed that the 30‐day and operative mortality rates were lower than those in previously published reports. The risk models developed in their study might contribute to improvements in procedure quality control and the establishment of a novel scoring system.[34](#ags312002-bib-0034){ref-type="ref"}

3.3. Prognostic impact of postoperative morbidity after gastric cancer surgery {#ags312002-sec-0013}
------------------------------------------------------------------------------

Several studies have reported a negative impact of postoperative complications on patient prognosis after gastric cancer surgery using multivariate analysis.[35](#ags312002-bib-0035){ref-type="ref"}, [36](#ags312002-bib-0036){ref-type="ref"}, [37](#ags312002-bib-0037){ref-type="ref"}, [38](#ags312002-bib-0038){ref-type="ref"}, [39](#ags312002-bib-0039){ref-type="ref"} Table [2](#ags312002-tbl-0002){ref-type="table-wrap"} and Figure [2](#ags312002-fig-0002){ref-type="fig"} show the summarized results of studies evaluating the prognostic impact of postoperative complications. All eligible studies reported adjusted hazard ratios obtained using multivariate analysis; the overall hazard ratio was 1.59 (95% CI, 1.13--2.24), with a statistically significant heterogeneity (*P *\< 0.0001). In each study, postoperative complications were defined by a Clavien‐Dindo grade higher than II,[34](#ags312002-bib-0034){ref-type="ref"}, [35](#ags312002-bib-0035){ref-type="ref"}, [36](#ags312002-bib-0036){ref-type="ref"}, [37](#ags312002-bib-0037){ref-type="ref"} which was observed in 10.3--14.5% of the studied patients. There were no apparent differences between the incidences of postoperative complications among large‐volume institutions in Japan. It is not clear from these reports if the occurrence of such complications was limited to Clavien‐Dindo grades III or higher (more severe complications). The prognoses of OS,[35](#ags312002-bib-0035){ref-type="ref"}, [39](#ags312002-bib-0039){ref-type="ref"} relapse‐free survival (RFS),[36](#ags312002-bib-0036){ref-type="ref"} both OS and oncological outcome,[37](#ags312002-bib-0037){ref-type="ref"} and both OS and RFS[38](#ags312002-bib-0038){ref-type="ref"} were evaluated. We found reports on the negative impact of postoperative complications on patient prognosis for every stage of gastric cancer,[36](#ags312002-bib-0036){ref-type="ref"} stage III gastric cancer,[37](#ags312002-bib-0037){ref-type="ref"} and stages II and III gastric cancers.[38](#ags312002-bib-0038){ref-type="ref"} Cancer‐related death is not commonly observed in the early stages of gastric cancer; thus, its negative impact on RFS might be characteristic of stage III gastric cancer patients.

###### 

Multivariate analyses of prognostic factors for patients after gastric cancer surgery

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                       Year   Country   Study type   Period       Tumor   No. patients   Complications                      Survival   Impact on survival   HR                     *P*‐value   Other factors
  ------------------------------------------------------------ ------ --------- ------------ ------------ ------- -------------- ---------------------------------- ---------- -------------------- ---------------------- ----------- -----------------------------------
  Li *et al*.[35](#ags312002-bib-0035){ref-type="ref"}         2013   China     RCS          2005--2006   GC      432            All postoperative complications\   OS         Negative             2.5 (1.8--3.6)         \<0.001     Stage
                                                                                                                                 12.5% (54/432)                                                                                        

  Hayashi *et al*.[36](#ags312002-bib-0036){ref-type="ref"}    2015   Japan     RCS          2000--2005   GC      502            Infectious complications\          RFS        Negative             1.958 (1.154--3.289)   0.013       ASA, age, stage
                                                                                                                                 10.3% (52/502) \> CDII                                                                                

  Kubota *et al*.[37](#ags312002-bib-0037){ref-type="ref"}     2014   Japan     RCS          2005--2008   GC      1395           Complications\                     OS, DSM    Negative             1.88 (1.26--2.80)      0.0018      Age, T, N, blood loss
                                                                                                                                 14.5% (202/1395) \> CDII                                                                              

  Tokunaga *et al*.[38](#ags312002-bib-0038){ref-type="ref"}   2013   Japan     RCS          2002--2006   GC      765            Intra‐abdominal infection\         OS, RFS    Negative             2.448 (1.475--4.060)   \<0.001     Stage
                                                                                                                                 10.6% (81/765) \> CDII                                                                                

  Jiang *et al*.[39](#ags312002-bib-0039){ref-type="ref"}      2014   China     RCS          2003--2008   GC      386            Complications\                     OS         Negative             1.453(1.079--1.956)    0.014       PNI, BMI, blood loss, T, N
                                                                                                                                 21.5% (83/386)                                                                                        

  Migita *et al*.[40](#ags312002-bib-0040){ref-type="ref"}     2013   Japan     RCS          2003--2009   GC      548            Complications\                     OS, RFS    No impact            1.31 (0.89--1.94)      0.172       PNI
                                                                                                                                 28.6% (157/548)                                                                                       

  Climent *et al*.[41](#ags312002-bib-0041){ref-type="ref"}    2015   Spain     RCS          1990--2009   GC      271            Complications\                     OS         No impact            0.76 (0.51--1.12)      0.167       
                                                                                                                                 59.8% (162/271) \> CDII                                                                               

  Saito *et al*.[42](#ags312002-bib-0042){ref-type="ref"}      2015   Japan     RCS          2001--2012   GC      305            Complications\                     RFS        No impact            1.10 (0.70--1.73)      0.682       CRP, adjuvant therapy, blood loss
                                                                                                                                 28.2% (86/305) \> CDII                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASA, American Society of Anesthesiologists; BMI, body mass index; CDII, Clavien‐Dindo grade II; CRP, C‐reactive protein; DSM, disease‐free survival; GC, gastric cancer; HR, hazard ratio; N, nodal staging; OS, overall survival; PNI, prognostic nutritional index; RCS, retrospective cohort study; RFS, relapse‐free survival; T, tumor depth.
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![Postoperative morbidity and long‐term survival after radical surgery for gastric cancer.](AGS3-1-11-g002){#ags312002-fig-0002}

However, some studies have found that postoperative complications do not always have a negative impact on prognosis.[40](#ags312002-bib-0040){ref-type="ref"}, [41](#ags312002-bib-0041){ref-type="ref"}, [42](#ags312002-bib-0042){ref-type="ref"} Migita *et al*. have focused on the prognostic nutritional index, and found that a reduction in the value of this index had a negative impact on the long‐term outcomes of gastric cancer patients. Climent *et al*. have analyzed the impact of postoperative complications on recurrence and survival after gastric cancer resection. In this study conducted in Spain, the incidence of postoperative complications (Clavien‐Dindo grade II or higher) was reported as 59.8%, which is somewhat higher than that reported elsewhere.[36](#ags312002-bib-0036){ref-type="ref"}, [37](#ags312002-bib-0037){ref-type="ref"}, [38](#ags312002-bib-0038){ref-type="ref"} They have concluded that these complications do not have a negative impact on oncological outcome. However, regional differences and patient background might be important in the interpretation of the incidence of postoperative complications.

In some reports, the incidence of postoperative complications is evaluated as a negative prognostic factor that affects not only the OS, but also the RFS of gastric cancer patients after curative surgery. In gastric cancer surgery, the major postoperative complications are anastomotic leakage and intra‐abdominal abscess as a result of pancreatic fistula and pneumonia. Adverse effects of postoperative complications on patient survival might be a result of excessive inflammation caused by the complications, stimulating the growth of residual cancer cells through some soluble factors. They might also be caused by reduced immune reaction against cancer cells. Presently, these speculations have not been confirmed. Saito *et al*.[42](#ags312002-bib-0042){ref-type="ref"} suggested that the actual event that affects patient survival might not be postoperative complications, but excessive inflammation after surgery. They have reported that a high level of postoperative C‐reactive protein is a more reliable indicator of survival after surgery than postoperative complications.

Another hypothesis must also be considered. If particularly frail patients with potentially poor prognoses easily develop postoperative complications, the incidence of these complications might not be an independent negative prognostic factor. Preoperative nutritional statuses of patients might contribute to this 'frailty'. Prognostic nutritional index I has been evaluated as a predictor of postoperative complications and poor prognosis.[39](#ags312002-bib-0039){ref-type="ref"} The hazard ratio of preoperative nutritional index for prognosis might be offset by the hazard ratio of postoperative complications. Jiang *et al*. have reported that postoperative complications are significant negative prognostic factors despite the negative impact of prognostic nutritional index shown in a multivariate analysis.[39](#ags312002-bib-0039){ref-type="ref"} In order to elucidate this phenomenon, the effect of prognostic nutritional index on the incidence of postoperative complications and patient survival should be studied in a large‐scale prospective setting.

The popularity of minimally invasive surgery for gastric cancer has been growing. The feasibility and non‐inferiority of laparoscopic gastrectomy have been compared with those of conventional open surgery. A phase‐II clinical trial of early‐stage gastric cancer (JCOG 0703[3](#ags312002-bib-0003){ref-type="ref"}) has shown that the incidences of anastomotic leakage and pancreatic fistula formation were acceptably low. Kim *et al*. have reported a decrease in morbidity after laparoscopic distal gastrectomy for stage I gastric cancer.[43](#ags312002-bib-0043){ref-type="ref"} However, the only significant factor was wound complication. Minimally invasive surgery might confer a benefit of low surgical stress (a small wound). However, the superiority of minimally invasive surgery is not definitively proven by a low incidence of postoperative complications correlating with good oncological outcomes. Sufficient level of surgical intervention, including appropriate extent of dissection, should be maintained. Robot‐assisted gastrectomy, an alternative to minimally invasive surgery, might reduce the incidence of postoperative complications;[44](#ags312002-bib-0044){ref-type="ref"} however, the benefits of this procedure, including its effect on oncological outcomes, has not been established to date.

3.4. Prognostic impact of postoperative morbidity after colorectal cancer surgery {#ags312002-sec-0014}
---------------------------------------------------------------------------------

Selected papers, published between 2011 and 2016, are summarized in Table [3](#ags312002-tbl-0003){ref-type="table-wrap"}, [45](#ags312002-bib-0045){ref-type="ref"}, [46](#ags312002-bib-0046){ref-type="ref"}, [47](#ags312002-bib-0047){ref-type="ref"}, [48](#ags312002-bib-0048){ref-type="ref"}, [49](#ags312002-bib-0049){ref-type="ref"}, [50](#ags312002-bib-0050){ref-type="ref"}, [51](#ags312002-bib-0051){ref-type="ref"}, [52](#ags312002-bib-0052){ref-type="ref"}, [53](#ags312002-bib-0053){ref-type="ref"}, [54](#ags312002-bib-0054){ref-type="ref"}, [55](#ags312002-bib-0055){ref-type="ref"}. These studies were cohort studies that conducted risk adjustment using multivariate analysis. Overall hazard ratio for postoperative OS was 1.55 (95% CI, 1.28--1.87) with a statistically significant heterogeneity (*P* = 0.0001) as shown in Figure [3](#ags312002-fig-0003){ref-type="fig"}. These results are consistent with those reported in a previous systematic review by Mirnezami *et al*.[14](#ags312002-bib-0014){ref-type="ref"} Mirnezami *et al*. have examined the effects of anastomotic leakage, obtaining odds ratios of 2.9 (95% CI, 1.78--4.71) for local recurrence, 1.38 (95% CI, 0.96--1.99) for distant recurrence, and 1.75 (95% CI, 1.47--2.1) for cancer‐specific survival. As the papers used in the two reviews do not overlap, these results might be reproducible.

###### 

Summary of studies reporting postoperative complications and oncological survival after colorectal cancer surgery

  Author                                                  Publication year   Country    Study design   Study period   Type of surgery   No. patients   Definition of complications                    Endpoint
  ------------------------------------------------------- ------------------ ---------- -------------- -------------- ----------------- -------------- ---------------------------------------------- -----------------
  Artinyan A[45](#ags312002-bib-0045){ref-type="ref"}     2015               USA        PBS            1999--2009     C + R             12 075         Infectious postoperative complications         OS
  Odermatt M[46](#ags312002-bib-0046){ref-type="ref"}     2014               UK         PCS            2003--2012     C + R             844            Major complications (CDIIIb or IV)             OS, DFS
  Xia X[47](#ags312002-bib-0047){ref-type="ref"}          2014               China      RCS            2006--2009     C (Laparosc.)     224            Postoperative complications (CDII or higher)   OS, RFS
  Nachiappan S[48](#ags312002-bib-0048){ref-type="ref"}   2015               UK         RCS            2004--2013     C + R             1048           Anastomotic leak                               OS, DFS
  Krarup PM[49](#ags312002-bib-0049){ref-type="ref"}      2014               Denmark    PBS            1988--2015     C                 8589           Anastomotic leak                               OS, LR, DR
  Lin JK[50](#ags312002-bib-0050){ref-type="ref"}         2011               Taiwan     RCS            1993--2003     R                 999            Anastomotic leak                               OS, DFS, CSS
  Smith JD[51](#ags312002-bib-0051){ref-type="ref"}       2012               USA        RCS            1991--2010     R                 1127           Anastomotic leak                               LR, DFS, OS
  Espín E[52](#ags312002-bib-0052){ref-type="ref"}        2015               Spain      PBS            2006--2008     R                 1181           Anastomotic leak                               OS, CSS, LR, OR
  Kang J[53](#ags312002-bib-0053){ref-type="ref"}         2015               S. Korea   RCS            2006--2009     R (Laparosc.)     1083           Anastomotic leak                               LR, DFS, OS
  Park EJ[54](#ags312002-bib-0054){ref-type="ref"}        2016               S. Korea   RCS            2005--2012     R (Laparosc.)     686            Complications CDI or higher                    LR, DFS, OS
  Jörgren F[55](#ags312002-bib-0055){ref-type="ref"}      2011               Sweden     PBS            1995--1997     R                 250            Anastomotic leak                               OS, CSS

C, colectomy; CSS, cancer‐specific survival; DFS, disease‐free survival; DR, distant recurrence; LR, local recurrence; OR, overall recurrence; OS, overall survival; PBS, population‐based study; PCS, prospective cohort study; R, rectal resection; RCS, retrospective cohort study.
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![Postoperative morbidity and long‐term survival after radical surgery for colorectal cancer](AGS3-1-11-g003){#ags312002-fig-0003}

There are several speculations that could explain the negative impact of postoperative complications on survival outcome. One of the most popular theories is that inflammatory cytokines, including interleukin (IL)‐1, IL‐6, and tumor necrosis factor (TNF), might promote tumor proliferation, survival, avoidance of apoptosis, progression of metastasis, and resistance to drug therapy. For example, Miki *et al*.[56](#ags312002-bib-0056){ref-type="ref"} have demonstrated that intense surgical stress and presence of an acute‐phase reactant were independently associated with the overexpression of IL‐6 in tumors. Another possible mechanism might be impairment in cell‐mediated immunity by systemic inflammation, resulting in the proliferation of metastatic tumor cells.[57](#ags312002-bib-0057){ref-type="ref"} It has also been proposed that intraluminal neoplastic cells might escape into the extraluminal space during an anastomotic leak, leading to implantation and local recurrence. Salvans *et al*.[58](#ags312002-bib-0058){ref-type="ref"} have conducted an interesting *in vitro* study using a colon cancer cell line to determine the effects of infected peritoneal fluid on migration and invasion of tumor cells. They have demonstrated that the fluid enhanced both cell migration and cell invasion compared with the non‐infected control.

3.5. Prognostic impact of BMI on postoperative morbidity and long‐term survival (Table [4](#ags312002-tbl-0004){ref-type="table-wrap"}) {#ags312002-sec-0015}
---------------------------------------------------------------------------------------------------------------------------------------

###### 

Prognostic impact of body mass index in gastroenterological cancer surgery

  Author                                                         Year                                              Type of cancer                                     No. patients   Conclusion
  -------------------------------------------------------------- ------ ------------------------------------------ -------------------------------------------------- -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Wang *et al*.[60](#ags312002-bib-0060){ref-type="ref"}         2015                                              Esophageal SCC                                     424            Preoperative BMI was an independent prognostic factor for OS and DFS. The proposed new prognostic model with the pN classification supplemented by BMI might improve the ability to predict ESCC patient outcome.
  Zogg *et al*.[62](#ags312002-bib-0062){ref-type="ref"}         2015                                              Various types of cancer                            529 955        Obese patients should be treated following the optimal oncological standards without being hindered by a misleading perception of prohibitively increased perioperative risk. Underweight and certain types of morbidly obese patients require targeted provision of appropriate care.
  Melis *et al*.[21](#ags312002-bib-0021){ref-type="ref"}        2015                                              Esophageal cancer                                  510            BMI did not affect the number of harvested lymph nodes, rates of negative margins, or morbidity and mortality after esophagectomy for cancer. Esophagectomy can be carried out safely and efficiently in mildly obese patients.
  Chen *et al*.[63](#ags312002-bib-0063){ref-type="ref"}         2015                                              Gastric cancer                                     1249           Despite an increased risk of mild postoperative complications, the high‐BMI patients exhibited paradoxically 'superior' survival outcomes in comparison with the normal‐BMI patients. These findings confirm the 'obesity paradox' in GC patients undergoing gastrectomy.
  Levolger *et al*.[73](#ags312002-bib-0073){ref-type="ref"}     2015                                              Gastrointestinal cancer and hepatobiliary cancer   2884           Sarcopenia identified before surgery is associated with impaired overall survival in gastrointestinal and hepatopancreatobiliary malignancies, and increases postoperative morbidity in patients with colorectal cancer with or without hepatic metastases.
  Pan *et al*.[64](#ags312002-bib-0064){ref-type="ref"}          2015                                              Esophageal cancer and gastric cancer               4823           H‐BMI has distinctly different effects on the postoperative survival of EAC and ESCC patients. H‐BMI is a potential predictor for improved prognosis in EC patients overall, and particularly in EAC patients, treated with curative esophagectomy. However, in ESCC patients, H‐BMI is a potential predictor for a poor prognosis of postoperative survival.
  Miao *et al*.[68](#ags312002-bib-0068){ref-type="ref"}         2015   .                                          Esophageal cancer                                  1342           A high BMI is not associated with increased overall morbidity following esophagectomy; moreover, it is associated with a decreased incidence of chylothorax. The improved overall survival of patients with high BMI in comparison with those with low BMI might be as a result of a relatively low pathological stage. A high BMI should not be a relative contraindication for esophagectomy.
  Ida *et al*.[65](#ags312002-bib-0065){ref-type="ref"}          2015                                              Esophageal cancer                                  138            Sarcopenia might be a predictor of pulmonary complications after esophagectomy. Further analysis is needed to clarify whether nutritional intervention improves skeletal muscle mass and thus contributes to reduction in postoperative respiratory complications in sarcopenic patients.
  Eom *et al*.[66](#ags312002-bib-0066){ref-type="ref"}          2014                                              Gastric cancer                                     4813           ABSI shows a good correlation with surgical complications in patients with gastric cancer. Further studies are needed to clarify the clinical significance of ABSI, and the results could help to determine the effect of abdominal obesity on gastric cancer surgery and the clinical usefulness of ABSI.
  Bickenbach *et al*.[67](#ags312002-bib-0067){ref-type="ref"}   2013                                              Gastric cancer                                     1853           Increased BMI is a predictor of increased postoperative complications, including anastomotic leak, but it is not a predictor of survival in gastric cancer.
  Zhang *et al*.[59](#ags312002-bib-0059){ref-type="ref"}        2013                                              Esophageal cancer                                  2031           Preoperative BMI is an independent prognostic factor for survival, strongly associated with postoperative complications in esophageal cancer.
  Hayashi Y[91](#ags312002-bib-0091){ref-type="ref"}             2010   *Cancer*. 116(24):5619--27, 2010 Dec 15.   Esophageal cancer                                  301            High BMI is common in EC patients. The improved OS/DFS noted in patients with high BMI might be a result of a low baseline clinical stage. Confirmation of these findings is warranted.
  Grotenhuis *et al*.[61](#ags312002-bib-0061){ref-type="ref"}   2010                                              Esophageal cancer                                  556            BMI has no prognostic value for short‐term and long‐term outcome in patients who undergo esophagectomy for cancer. It is not an independent predictor for radical R0 resection. Patients oncologically eligible for esophagectomy should not be denied surgery on the basis of their BMI class.

ABSI, A Body Shape Index; BMI, body mass index; DFS, disease‐free survival; EC, esophageal cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; H‐BMI, high BMI; OS, overall survival; SCC, squamous cell carcinoma.
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Multivariate analyses carried out in various studies have shown that preoperative BMI is an independent prognostic factor for reduced survival, and that it is strongly associated with postoperative complications in esophageal cancer.[59](#ags312002-bib-0059){ref-type="ref"} Wang *et al*.[60](#ags312002-bib-0060){ref-type="ref"} have reported that preoperative BMI is an independent prognostic factor for OS and disease‐free survival (DFS). Their proposed new prognostic model with the pN classification supplemented by BMI might improve the ability to predict outcomes for esophageal squamous cell carcinoma patients.

However, we identified several studies showing that high BMI does not worsen the long‐term oncological outcome. Grotenhuis *et al*.[61](#ags312002-bib-0061){ref-type="ref"} reported that BMI was not of prognostic value for short‐ and long‐term outcomes in patients who underwent esophagectomy for cancer and it is not an independent predictor for radical (R0) resection. Patients oncologically eligible for esophagectomy should not be denied surgery on the basis of their BMI class. Zogg *et al*.[62](#ags312002-bib-0062){ref-type="ref"} also suggested that outcomes after major resection for cancer suggest that obese patients should be treated according to optimal oncological standards. Their treatment should not be hindered by a misleading perception of prohibitively high perioperative surgical risk. However, the authors have noted that underweight patients and certain types of morbidly obese individuals require targeted provision of appropriate care.

Interestingly, Chen *et al*.[63](#ags312002-bib-0063){ref-type="ref"} have concluded that high‐BMI patients exhibit paradoxically 'superior' survival outcomes compared with normal‐BMI patients despite the higher risk of mild postoperative complications. These findings confirm the 'obesity paradox' in gastric cancer patients undergoing gastrectomy. Pan *et al*.[64](#ags312002-bib-0064){ref-type="ref"} reported that high BMI has distinctly different effects on postoperative survival of esophageal adenocarcinoma and esophageal squamous cell carcinoma patients. Overall, high BMI is a potential predictor of improved prognosis in esophageal cancer patients, particularly in esophageal adenocarcinoma patients treated with curative esophagectomy. However, in patients with esophageal squamous cell carcinoma, a high BMI is a predictor of poor prognosis of postoperative survival. Ida *et al*.[65](#ags312002-bib-0065){ref-type="ref"} reported that sarcopenia might be a predictor of pulmonary complications after esophagectomy. Further analysis is required to elucidate whether nutritional intervention improves skeletal muscle mass and thus contributes to the reduction of postoperative respiratory complications in sarcopenic patients.

Eom *et al*.[66](#ags312002-bib-0066){ref-type="ref"} have reported that the A Body Shape Index (ABSI), rather than BMI, correlates with surgical complications in patients with gastric cancer. Further studies are required to elucidate the clinical significance of ABSI; the results might help determine the effect of abdominal obesity on gastric cancer surgery outcome and the clinical usefulness of this index.[67](#ags312002-bib-0067){ref-type="ref"} Enhanced BMI is a predictor of increased postoperative complications, including anastomotic leak, but it is not a predictor of survival in gastric cancer. Melis *et al*.[21](#ags312002-bib-0021){ref-type="ref"} have reported that BMI does not affect the number of harvested lymph nodes, rates of negative margins, and morbidity and mortality after esophagectomy for cancer. In their experience, esophagectomy can be carried out safely and efficiently in mildly obese patients. Miao *et al*.[68](#ags312002-bib-0068){ref-type="ref"} have shown that high BMI is not associated with increased overall morbidity following esophagectomy; however, it is associated with a decreased incidence of chylothorax. However, better OS observed in patients having high BMI compared with those having low BMI might be attributed to a relatively low pathological stage. In summary, a high BMI should not be a relative contraindication for esophagectomy.

It has been shown that after colorectal resection, low BMI has a detrimental effect on long‐term survival. Toiyama *et al*. have revealed that a BMI \<20 is associated with reduced OS and DFS after laparoscopic resection.[69](#ags312002-bib-0069){ref-type="ref"} Adachi *et al*.[70](#ags312002-bib-0070){ref-type="ref"} demonstrated in elderly (≥80 years) colorectal cancer patients (stage 0 to III) that a BMI \<18.5 is associated with decreased OS and cancer‐specific survival. Uratani *et al*.[71](#ags312002-bib-0071){ref-type="ref"} studied stage I--III patients undergoing laparoscopic resection and found that a BMI \<20 is correlated with reduced DFS and OS. Doleman *et al*. have recently conducted a meta‐analysis on the effects of BMI following the diagnosis of colorectal cancer. They have reported that a low BMI is associated with increased all‐cause mortality and cancer‐specific mortality.[72](#ags312002-bib-0072){ref-type="ref"} This suggests that underweight patients might have lower nutritional statuses and lower body muscle content than individuals with normal bodyweight.

In addition to the low BMI, sarcopenia, defined as decreased muscle content, also has a negative impact on oncological outcome. Levolger *et al*.[73](#ags312002-bib-0073){ref-type="ref"} have reported that sarcopenia identified before surgery using single‐slice computed tomography, is associated with impaired OS in gastrointestinal and hepatopancreatobiliary malignancies. Sarcopenia also increases postoperative morbidity in patients with colorectal cancer with or without hepatic metastases.[73](#ags312002-bib-0073){ref-type="ref"}

3.6. Strategy for reducing the morbidity rate for improved oncological outcome {#ags312002-sec-0016}
------------------------------------------------------------------------------

We found that postoperative sepsis was the only major postoperative event associated with long‐term mortality. Postoperative sepsis might reflect a deep impairment in the immune response, which might increase cancer recurrence and mortality.[20](#ags312002-bib-0020){ref-type="ref"} Therefore, minimizing surgical stress and/or levels of inflammatory mediators might reduce postoperative complications and improve oncological outcome. Following this working hypothesis, perioperative steroid therapy has been evaluated in patients who had undergone esophagectomy. Perioperative steroid therapy reduces postoperative morbidity but does not improve long‐term survival in patients with thoracic esophageal cancer.[15](#ags312002-bib-0015){ref-type="ref"}, [16](#ags312002-bib-0016){ref-type="ref"}, [74](#ags312002-bib-0074){ref-type="ref"} Early administration of sivelestat in patients receiving radical surgery for esophageal cancer can inhibit postoperative systemic inflammatory reactions, and it might also have a beneficial effect on prognosis.[75](#ags312002-bib-0075){ref-type="ref"}, [76](#ags312002-bib-0076){ref-type="ref"} Some of the examined factors did not differ between the treated and control groups, including IL‐8 on postoperative day 1, IL‐6 before the surgery and on postoperative day 5, PaO~2~/FiO~2~ following the surgery, mortality, anastomotic leakage, severe infection, and renal and hepatic failure. Giving prophylactic methylprednisolone during the perioperative period might reduce the incidence of specific types of postoperative complications and inhibit the postoperative inflammatory reaction. However, additional randomized controlled trials should be done to evaluate this strategy.[77](#ags312002-bib-0077){ref-type="ref"} Ulinastatin prevents postoperative complications and immunosuppression in esophagectomy patients, thereby prolonging RFS.[78](#ags312002-bib-0078){ref-type="ref"} Yamana *et al*.[79](#ags312002-bib-0079){ref-type="ref"} have shown that an intensive preoperative respiratory rehabilitation program can reduce postoperative pulmonary complications in esophageal cancer patients. Giving postoperative ghrelin can effectively inhibit the activity of inflammatory mediators and improve postoperative clinical course in patients with esophageal cancer.[80](#ags312002-bib-0080){ref-type="ref"} Furthermore, treatment with IL‐1β or lipopolysaccharide enhances the expression of IL‐6 protein in a human colonic cancer cell line, Caco‐2. This overexpression is abrogated by additional presupplementation of IL‐1RA. Moreover, Elaraj *et al*.[81](#ags312002-bib-0081){ref-type="ref"} have demonstrated that IL‐1RA inhibits the growth of colonic adenocarcinoma cell line xenografts in nude mice. Application of anti‐inflammatory therapy as described above is one of the promising strategies for future cancer treatment, with a likelihood of reducing morbidity rates and improving oncological outcomes.

3.7. Future perspectives {#ags312002-sec-0017}
------------------------

Although postoperative complications have been associated with impaired long‐term survival after gastrointestinal cancer resections, we must also consider their indirect effects. Adjuvant chemotherapy might sometimes be terminated or delayed in patients who develop postoperative complications. Furthermore, patients with multiple comorbidities or with poor nutritional statuses might have a tendency to develop postoperative complications as well as late mortality. Therefore, the preoperative physiological status can be a confounding factor in the evaluation of postoperative complications and late mortality. Richards *et al*.[82](#ags312002-bib-0082){ref-type="ref"} have analyzed the effects of various perioperative factors on disease recurrence in patients with colorectal cancer. In their prediction model of postoperative complications, they used the Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) system and the modified Glasgow Prognostic Score for systemic inflammatory response markers.[83](#ags312002-bib-0083){ref-type="ref"} POSSUM comprises a physiological score and an operative score. The physiological score includes 11 variables of vital signs and laboratory data. The operative score includes six variables of the operation and tumor stage. The modified Glasgow Prognostic Score ranges from 0 to 2 depending on the abnormality of preoperative C‐reactive protein and serum albumin levels. The authors found that the POSSUM physiological score and the modified Glasgow Prognostic Score, but not postoperative complications, are the independent predictors of DFS. In patients with gastric cancer, the Glasgow Prognostic Score has also been associated with long‐term survival.[37](#ags312002-bib-0037){ref-type="ref"} Similarly, the Estimation of Physiological Ability and Surgical Stress scores[84](#ags312002-bib-0084){ref-type="ref"} were associated with OS following gastrointestinal cancer resection.[85](#ags312002-bib-0085){ref-type="ref"}, [86](#ags312002-bib-0086){ref-type="ref"}, [87](#ags312002-bib-0087){ref-type="ref"}

The association between postoperative complications and reduced long‐term survival in gastrointestinal cancer patients, whether or not these complications are detrimental for long‐term survival, remains to be established owing to unmeasured confounders. It is possible that compromised statuses (potential confounders) simply cause postoperative complications as well as late mortality (Fig. [4](#ags312002-fig-0004){ref-type="fig"}). For example, a diabetes mellitus patient with interstitial pneumonitis will have an increased chance of postoperative complications and a higher risk of tumor‐related and unrelated death. To clarify the doubts persisting in this field, a large‐scale prospective cohort study should be conducted. Such a study should use a statistical method (e.g. propensity score adjustment) accounting for preoperative physiological status as well as systemic inflammatory response. As shown in Figure [4](#ags312002-fig-0004){ref-type="fig"}, scanty adjuvant therapy is also considered one of the key intermediate factors affecting postoperative complications and long‐term prognosis. Greenleaf *et al*. have found that adjuvant therapy improves patient survival compared with patients not undergoing such therapy. However, the period before the initiation of adjuvant therapy did not affect survival among the treated patients.[88](#ags312002-bib-0088){ref-type="ref"} Adjustments of intermediate variables in the standard statistical models should be conducted with caution because of a potential over‐adjustment bias.[89](#ags312002-bib-0089){ref-type="ref"} Recently, we carried out a mediation analysis to establish whether the effect of exposure on a particular outcome is mediated by a hypothesized intermediate variable.[90](#ags312002-bib-0090){ref-type="ref"} Using such methods might shed some light on the causal relationship between postoperative complications and reduced long‐term survival.

![Relationship between postoperative complications and long‐term survival following gastrointestinal cancer resection](AGS3-1-11-g004){#ags312002-fig-0004}

In conclusion, our literature review suggests that severe postoperative morbidities are associated with impaired long‐term prognosis. Avoiding such complications after radical surgery might improve oncological outcomes. Because there are no large‐scale prospective cohort studies in this field, further multi‐institutional prospective studies should be carried out.
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